<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04883775</url>
  </required_header>
  <id_info>
    <org_study_id>20-342</org_study_id>
    <nct_id>NCT04883775</nct_id>
  </id_info>
  <brief_title>Study of a New Technique for Imaging Pancreatic Cancer</brief_title>
  <official_title>89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging in Pancreatic Cancer or Other CA19-9 Positive Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioNTech SE</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to see how well the experimental imaging agent&#xD;
      89Zr-DFO-HuMab-5B1 attaches to pancreatic tumors, and to find out whether PET/CT scans done&#xD;
      with this imaging agent produce better images of cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This is a phase I, open label, nonrandomized, dose-escalation trial of a fixed dose of MVT-2163 (89Zr-DFO-HuMab-5B1) and varying antibody masses of MVT-5873 (HuMab-5B1), designed to identify an optimal dose (total antibody mass) and optimal timing, for tumor imaging. This trial will include dose escalation, which includes up to 5 cohorts, an expansion phase, a re-entry phase, and a pre-surgery phase.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjects with treatment-related adverse events as assessed</measure>
    <time_frame>1 year</time_frame>
    <description>assessed by CTCAE v4.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Biodistribution of MVT-2163</measure>
    <time_frame>1 year</time_frame>
    <description>will be determined by measuring radiation exposure for key organs and tissues</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Pancreatic Cancer</condition>
  <condition>Tumors That Express CA19-9</condition>
  <arm_group>
    <arm_group_label>89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive a single, fixed, intravenous dose of MVT-2163, consisting of 3 mg (nominal mass - actual mass administered will likely vary between 2.0 and 2.5 mg) of MVT-2163 radiolabeled from 5 mCi to no less than 1.0 mCi (adjusted as of 16-Mar 2017) of 89Zr.Cohort 1 subjects will receive MVT-2163, with no MVT-5873 pre-dosing. Subjects in subsequent cohorts 2 and 3 will receive a dose of MVT-5873 15 minutes, ~ 2 hours, and ~4 hours prior to administration of MVT-2163. Future cohorts 4 and 5 may evaluate alternate time frames. Other cohorts may evaluate administration of MVT-5873 one week prior (D-7) to the day of MVT-2163 administration and a second administration of MVT-5873 the day of (D0) MVT-2163 administration. The re-entry (RE) and pre-surgery (PS) cohorts will administer MVT-2163 3 ± 1 hour after administration of MVT-5873.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVT-2163</intervention_name>
    <description>MVT-2163 is administered intravenously as a PET imaging agent.</description>
    <arm_group_label>89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging</arm_group_label>
    <other_name>89Zr-DFO-HuMab-5B1</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MVT-5873</intervention_name>
    <description>MVT-5873 will be administered intravenously over at least 60 minutes.</description>
    <arm_group_label>89Zr-DFO-HuMab-5B1 (MVT-2163) Imaging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        PART I : ESCALATION, EXPANSION, RE-ENTRY COHORTS:&#xD;
&#xD;
          -  Histologically confirmed, locally-advanced, or metastatic pancreatic ductal&#xD;
             adenocarcinoma (PDAC) or other malignancies known to express CA19-9 positive&#xD;
             malignancies&#xD;
&#xD;
        PART II: PRE-SURGERY COHORT ONLY:&#xD;
&#xD;
          -  Biopsy-proven or high suspicion on imaging for pancreatic ductal adenocarcinoma (PDAC)&#xD;
             (Stage T2 and T3) and&#xD;
&#xD;
          -  Patient scheduled to undergo surgery as standard of care for their pancreatic&#xD;
             adenocarcinoma OR&#xD;
&#xD;
          -  Patients with Intraductal papillary mucinous neoplasm (IPMN) scheduled to undergo&#xD;
             surgery as standard of care.&#xD;
&#xD;
        The suspicion for pancreatic carcinoma and decision for surgery will be based on review of&#xD;
        imaging and clinical findings in the disease management team discussion including surgeon&#xD;
        and radiologist.&#xD;
&#xD;
        PART I and II:&#xD;
&#xD;
          -  Signed, informed consent&#xD;
&#xD;
          -  Age 18 or more years&#xD;
&#xD;
          -  At least one lesion by CT or MRI ≥ 2 cm, unless determine otherwise for pre-surgery&#xD;
             cohort subjects&#xD;
&#xD;
          -  CA19-9 serum level:&#xD;
&#xD;
               -  For Part I: &gt;ULN or CA19-9 positive biopsy (optional);&#xD;
&#xD;
               -  For Part II ( presurgical cohort): CA19-9 serum level (normal or high levels are&#xD;
                  allowed) or CA19-9 positive biopsy (optional)&#xD;
&#xD;
          -  ECOG performance status of 0 to 2&#xD;
&#xD;
          -  Adequate laboratory parameters including:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1.5 x 10^9/L&#xD;
&#xD;
               -  Hemoglobin ≥ 9.0 g/dL (in the absence of red blood cell transfusions in the prior&#xD;
                  14 days)&#xD;
&#xD;
               -  Platelet count &gt;75,000/ mm^3&#xD;
&#xD;
               -  AST/SGOT, ALT/SGPT ≤2.5 x ULN, unless liver metastases are clearly present, then&#xD;
                  ≤5.0 x ULN&#xD;
&#xD;
               -  Total bilirubin ≤1.5x the upper limit of normal unless considered due to&#xD;
                  Gilbert's syndrome in which case, ≤3x the upper limit of normal&#xD;
&#xD;
               -  Creatinine (serum or plasma) ≤ 1.5 x ULN or eGFR&gt;50 mL/min&#xD;
&#xD;
        PART I: ESCALATION, EXPANSION, RE-ENTRY COHORTS:&#xD;
&#xD;
          -  Willingness to participate in collection of pharmacokinetic samples&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Major surgery other than diagnostic surgery within 4 weeks of Study Day 1&#xD;
&#xD;
          -  History of anaphylactic reaction to human, or humanized, antibody&#xD;
&#xD;
          -  Other on-going cancer therapy or investigational agents (except MVT-5873)&#xD;
&#xD;
          -  Known history of HIV&#xD;
&#xD;
          -  Pregnant or currently breast-feeding&#xD;
&#xD;
          -  Psychiatric illness/social situations that would interfere with compliance with study&#xD;
             requirements&#xD;
&#xD;
          -  Prior entry onto this protocol 3 or more times (e.g., subjects may enter this protocol&#xD;
             and be imaged up to 3 times)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neeta Pandit-Taskar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neeta Pandit-Taskar, MD</last_name>
    <phone>212-639-3046</phone>
    <email>pandit-n@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jason Lewis, PhD</last_name>
    <phone>646-888-3080</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Neeta Pandit-Taskar, MD</last_name>
      <phone>212-639-3046</phone>
    </contact>
    <contact_backup>
      <last_name>Jason Lewis, PhD</last_name>
      <phone>646-888-3080</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>May 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>89Zr-DFO-HuMab-5B1 (MVT-2163)</keyword>
  <keyword>Imaging</keyword>
  <keyword>MVT-5873</keyword>
  <keyword>20-342</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

